Examines HIV/HCV prevalence in men who inject drugs, suggesting RDS efficiently identifies cases over time.
BACKGROUND: People who inject drugs (PWID) face disproportionate burdens of HIV and hepatitis C (HCV) yet remain underserved by services. In India, population-level data on HIV/HCV prevalence and service engagement among PWID remain scarce. Respondent-driven sampling (RDS) enables population-level inference, however evidence on RDS performance with non-fixed sample sizes remains limited. METHODS: We examined RDS performance from December 2017 to December 2018 among PWID in Varanasi, India. Participants completed HIV and HCV testing and interviewer-administered surveys on service engagement. Using RDS-II weights, we estimated HIV/HCV prevalence and care continuum outcomes, and analyzed trends across enrollment quarters. RESULTS: RDS recruited 1,249 men who inject drugs across 22 waves. HIV prevalence was 7%, HCV prevalence was 12%. Overall, 6% were living with HIV/HCV co-infection. Two initial seeds were HIV and HCV negative. HIV positivity was 36% in Q1 declining to 1% in Q4; HCV positivity declined from 46% in Q1 to 3% in Q4. Service utilization was low, yet highest in Q1. Among participants living with HIV, 33% were aware of their status, 15% on antiretroviral therapy, and 11% virally suppressed. HCV care engagement was lower, with 3% aware of their status and 2% having initiated care. CONCLUSION: RDS identified PWID living with HIV/HCV most efficiently in Q1, highlighting how time-sensitive RDS methodology may be. Identifying well-connected seeds can be pivotal for early case detection. Monitoring recruitment trends may optimize case-finding and improve linkage to care using RDS, supporting efforts to improve quality of life for PWID and manage global HIV and HCV burdens.
No takes yet. Share an insight, caveat, or question.
Kaptchuk et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: